key: cord-0016354-t1pvnzux
authors: Benotmane, Ilies; Gautier -Vargas, Gabriela; Cognard, Noelle; Olagne, Jerome; Heibel, Francoise; Braun-Parvez, Laura; Martzloff, Jonas; Perrin, Peggy; Moulin, Bruno; Fafi-Kremer, Samira; Caillard, Sophie
title: Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
date: 2021-03-26
journal: Kidney Int
DOI: 10.1016/j.kint.2021.03.014
sha: 59146b4710632e6b79158436d8bc14a3f5c03420
doc_id: 16354
cord_uid: t1pvnzux

nan

International recommendations on COVID-19 vaccine distribution have given priority to immunocompromised patients -including kidney transplant recipients (KTRs). 1, 2 Unfortunately, this guidance has been released without inclusion of this clinical population in vaccine clinical trials. In an effort to shed light on the efficacy and safety of an mRNA COVID-19 vaccine in KTRs, this preliminary study was undertaken to investigate the anti-SARS-CoV-2 antibody response after the first injection.

We examined 242 KTR who received the first injection of the Moderna mRNA-1273 vaccine (100 µg) at the Strasbourg University Hospital (France) between January 21 and 28, 2021. All had a negative history for COVID-19 and tested negative for anti-SARS-CoV-2 antibodies on the day of the first injection. The anti-SARS-CoV-2 antibody response against the spike protein was assessed at 28 days post-injection using the ARCHITECT IgG II Quant test (Abbott, Abbott Park, IL, USA), with titers >50 arbitrary units per mL (AU/mL) being considered as positive (detection range: 6.8-40000 AU/mL); positive agreement, 99.4%; negative agreement, 99.6%).

One patient developed mild symptomatic COVID-19 seven days after injection and only 26 (10.8%) KTRs had a positive serology at 28 days post-injection. The median IgG titer was 224 AU/mL (interquartile range: 76−496 AU/mL), whereas the median IgG titer in the seronegative group was < 6.8 AU/mL ( Figure 1 ). Patients who seroconverted had longer time from transplantation, received less immunosuppression, and had a better kidney function (Table 1 ).

In summary, the burden of immunosuppression may induce a weak anti-SARS-CoV-2 antibody response in KTRs after the first injection of an mRNA COVID-19 vaccine. This finding is strikingly different compared with immunocompetent subjects -who invariably seroconverted after the first injection. 3, 4 We highlight the need not to delay the second vaccine J o u r n a l P r e -p r o o f injection in immunocompromised patients. Close surveillance is also recommended to discuss the opportunity of a third dose in less responsive patients. 

COVID-19 Vaccination Program Operational Guidance | CDC

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine